Qiagen, Hilden, Germany, has launched QCI Precision Insights in the European market. The service includes European Society for Medical Oncology (ESMO) guidelines and the European Medicines Agency (EMA)-approved oncology drugs catalog.
Jonathan Sheldon, PhD, Qiagen.
QCI Precision Insights is a clinical interpretation service provided by a team of molecular biologists and oncologists who translate molecular data specific to each patient into state-of-the-art clinical insights and therapeutic options. Capable of rapidly interpreting any size panel on any testing platform, QCI Precision Insights enables molecular pathologists and oncologists in Europe to match complex genomic test data to relevant, geographically-matched treatment options for evidence-based, individualized treatment recommendations in record time.
“With the growing demand for molecular testing in the clinic, there is a continuous struggle to keep pace. With the finalized integration of N-of-One and their somatic interpretation service into the QCI product line, we can now meet this demand,” says Jonathan Sheldon, PhD, senior vice president of Qiagen digital insights. QCI Precision Insights offers:
- Variant- and gene-specific information, with direct reference to EMA drug approvals and ESMO guidelines.
- EMA-approved drug summaries and approved indications.
- ESMO clinical practice guidelines.
- Up-to-date treatments approved by EMA.
- Demographically relevant European clinical trials.
“Molecular pathologists can now off-load interpretation work and reduce clinical test interpretation time by as much as 85%,” adds Sheldon. “So far, over 175,000 oncology cases have been processed by QCI Precision Insights, and I’m excited to see how Europe will embrace this new opportunity to transform the way molecular pathologists intersect with the cancer care continuum.”
For more information, visit Qiagen.
